These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38441378)

  • 1. Role of toll-like receptors in the pathogenesis of COVID-19: Current and future perspectives.
    Yang MY; Zheng MH; Meng XT; Ma LW; Liang HY; Fan HY
    Scand J Immunol; 2023 Aug; 98(2):e13275. PubMed ID: 38441378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Toll-like receptors in the pathogenesis of COVID-19.
    Khanmohammadi S; Rezaei N
    J Med Virol; 2021 May; 93(5):2735-2739. PubMed ID: 33506952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.
    Mantovani S; Oliviero B; Varchetta S; Renieri A; Mondelli MU
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.
    Patra R; Das NC; Mukherjee S
    Adv Exp Med Biol; 2021; 1352():87-109. PubMed ID: 35132596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.
    Jung HE; Lee HK
    Viruses; 2021 Oct; 13(11):. PubMed ID: 34834939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Expression Patterns of Toll-like Receptors in COVID-19 Patients.
    Lee N; Ko R; Lee SY
    Front Biosci (Landmark Ed); 2023 Nov; 28(11):307. PubMed ID: 38062845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
    Choudhury A; Mukherjee S
    J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans.
    Choudhury A; Das NC; Patra R; Mukherjee S
    J Med Virol; 2021 Apr; 93(4):2476-2486. PubMed ID: 33404091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.
    Totura AL; Whitmore A; Agnihothram S; Schäfer A; Katze MG; Heise MT; Baric RS
    mBio; 2015 May; 6(3):e00638-15. PubMed ID: 26015500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments.
    Liu ZM; Yang MH; Yu K; Lian ZX; Deng SL
    Front Pharmacol; 2022; 13():989664. PubMed ID: 36188605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
    Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
    Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Effects of Toll-Like Receptor Signaling on the Activation of Immune Responses in the Upper Respiratory Tract.
    Xu M; Li N; Fan X; Zhou Y; Bi S; Shen A; Wang B
    Microbiol Spectr; 2022 Feb; 10(1):e0114421. PubMed ID: 35196817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines.
    Mathew DS; Pandya T; Pandya H; Vaghela Y; Subbian S
    Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From defense to offense: Modulating toll-like receptors to combat arbovirus infections.
    Lani R; Thariq IM; Suhaimi NS; Hassandarvish P; Abu Bakar S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2306675. PubMed ID: 38263674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.